분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-05-21 18:41:11 , Hit : 1917
 Novartis licenses Ophthotech eye drug in $1bn deal ('anti-PDGF APTAMER' as AMD drug)



Fovista is a potential first-in-class treatment for wet AMD

May 20, 2014

Novartis

Novartis has fleshed out its portfolio of drugs for diseases of the eye by licensing Ophthotech's Fovista in a deal valued at around $1bn.

The Swiss pharma giant has licensed rights to Fovista (anti-PDGF aptamer) outside the US in a deal that brings Ophthotech $200m upfront, another $130m in near-term milestones and $700m-plus in potential regulatory and commercial payments.

Fovista is claimed to be the closest to market of all anti-PDGF (platelet derived growth factor) drugs in development and could be a first-in-class therapy for the wet form of age-related macular degeneration (AMD), a leading cause of acquired blindness.

Novartis already sells anti-VEGF (vascular endothelial growth factor) drug Lucentis (ranibizumab) for wet AMD - as well as other indications such as pathological myopia and macular oedema - and achieved sales of more than $4bn with the brand in 2013, making it the 19th biggest-selling drug on the market according to the PMLiVE Top Pharma List.

Competition in the AMD sector is on the increase, however, with Lucentis jostling for market share with Regeneron and Bayer's Eylea (aflibercept) as well as off-label use of Roche's Avastin (bevacizumab), so the Ophthotech deal gives Novartis an alternative therapeutic option as well as the possibility of developing a combination treatment.

Novartis and Ophthotech confirmed that Fovista would also be developed as a fixed-dose combination with "a Novartis proprietary anti-VEGF product" as well as new formulations of the drug such as a prefilled syringe version.

As a single agent for wet AMD Fovista is currently in three phase III trials involving more than 1,800 patients that are due to generate top-line data in 2016.

Ophthotech has retained rights to the drug in the US and will also earn royalties on overseas sales. The firm's chief executive David Guyer said the deal was the largest ex-US partnering deal ever in the biotechnology industry and "potentially transformational" for the company.







887   존재하지 않았던 STAP 줄기세포  이성욱 2014/06/05 1664
886   금발은 어떻게 생겨날까? - DNA 글자 하나가 머리칼의 색깔을 바꾼다.  이성욱 2014/06/05 1649
885   광범위 목록화로 새로운 사람 단백질 193개 확인  이성욱 2014/06/02 1456
884   Pfizer Abandons AstraZeneca Takeover Bid  이성욱 2014/05/29 1655
883   흉선의 종양억제 과정에 작용하는 다윈주의(자연선택) 메커니즘  이성욱 2014/05/27 2326
882   DNA의 규칙을 배반한 미생물  이성욱 2014/05/27 1591
881   [바이오토픽] 「미토콘드리아 대체」: 초읽기에 들어간 '부모가 셋인 아기' 탄생  이성욱 2014/05/26 2514
880   DNA가 비슷한 배우자를 선택하는 경향  이성욱 2014/05/23 1655
  Novartis licenses Ophthotech eye drug in $1bn deal ('anti-PDGF APTAMER' as AMD drug)  이성욱 2014/05/21 1917
878   암 미세환경의 저산소증으로 인한 PD-L1 의 발현  이성욱 2014/05/20 2427
877   단순 포진 바이러스 탑재 줄기세포로 악성 뇌종양 치료를?  이성욱 2014/05/19 2102
876   항체 생성은 위험 신호일 때만  이성욱 2014/05/19 1615
875   암 백신과 항체 치료의 항암 효과  이성욱 2014/05/19 2133
874   Top 100 Most Prescribed, Top Selling Drugs  이성욱 2014/05/15 3073
873   마우스에서 뇌종양의 성장을 조절하는 단백질 발견  이성욱 2014/05/14 1956
872   외계의` DNA를 가진 최초의 생명체 탄생  이성욱 2014/05/14 1868
871   항-EGFR 항체 치료의 저항성을 극복하는 새로운 대장암 치료제  이성욱 2014/05/13 2355
870   Regeneron to Use Avalanche Platform in $640M+ Gene Therapy Collaboration  이성욱 2014/05/07 1620
869   인지과학의 수수께끼: 말(言)이 먼저일까, 생각이 먼저일까?  이성욱 2014/05/07 1643
868   DNA의 복사 기계가 일시 정지하는 경우, 암이 될 수 있어?  이성욱 2014/05/07 1769

[이전 10개] [1]..[11][12][13][14][15][16][17][18][19] 20 ..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN